Organogenesis (NASDAQ:ORGO) Shares Up 10.8% – Still a Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares traded up 10.8% on Friday . The stock traded as high as $4.10 and last traded at $4.15. 632,813 shares traded hands during trading, a decline of 42% from the average session volume of 1,095,408 shares. The stock had previously closed at $3.75.

Analysts Set New Price Targets

Separately, Morgan Stanley boosted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Organogenesis Stock Up 13.6 %

The company has a 50-day moving average of $4.32 and a two-hundred day moving average of $3.68. The company has a market capitalization of $540.29 million, a PE ratio of -71.00 and a beta of 1.79. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company’s stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 36.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ORGO. Soleus Capital Management L.P. raised its stake in Organogenesis by 5.4% during the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock valued at $39,952,000 after purchasing an additional 645,000 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after buying an additional 1,035,120 shares during the period. Dimensional Fund Advisors LP grew its stake in Organogenesis by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock worth $8,925,000 after purchasing an additional 442,772 shares in the last quarter. State Street Corp grew its position in shares of Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after buying an additional 9,090 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Organogenesis by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock valued at $3,435,000 after purchasing an additional 255,600 shares during the period. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.